Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, double blind , multicenter trial comparing tegoprazan 25 mg with lansoprazole 15 mg as maintenance therapy in healed erosive oesophagitis

Next Previous
Search
Trial Profile

A phase 3, double blind , multicenter trial comparing tegoprazan 25 mg with lansoprazole 15 mg as maintenance therapy in healed erosive oesophagitis

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lansoprazole (Primary) ; Tegoprazan (Primary)
  • Indications Erosive oesophagitis
  • Focus Therapeutic Use

Most Recent Events

  • 03 Nov 2022 New trial record
  • 31 Oct 2022 Results published in the Alimentary Pharmacology and Therapeutics
  • 11 Oct 2022 Post hoc analysis assessing to compare tegoprazan 25 mg to lansoprazole 15 mg as maintenance therapy in healed erosive esophagitis presented at the 30th United European Gastroenterology Week

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top